Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO - Seite 2

The data suggest that the combination of tiragolumab plus Tecentriq was well-tolerated, showing similar rates of all Grade 3 or more all-cause adverse events (AEs) when combining the two immunotherapies compared with Tecentriq alone (41.8% vs 44.1%).

At a six-month follow-up, the improvement in the ORR and PFS in the tiragolumab plus Tecentriq arm persisted in both the ITT and the PD-L1-high populations, and no new safety signals were observed.
As part of Roche’s commitment to explore new immunotherapy options and combinations, the company recently initiated two Phase III clinical trials evaluating tiragolumab plus Tecentriq for people with certain types of lung cancer (SKYSCRAPER-01 and SKYSCRAPER-02). Tiragolumab is also being evaluated in other solid tumours as well as in hematological cancers. Additional Phase 1a/b results in solid tumours will be presented at an upcoming medical meeting.

About CITYSCAPE study ¹
CITYSCAPE is a global Phase II, randomised and blinded study evaluating tiragolumab plus Tecentriq compared with Tecentriq alone in 135 patients with first-line PD-L1-positive, locally advanced unresectable or metastatic non-small cell lung cancer. Patients were randomised 1:1 to receive either tiragolumab plus Tecentriq or placebo plus Tecentriq, until progressive disease or loss of clinical benefit. Co-primary endpoints are ORR and PFS. Secondary endpoints include safety and overall survival. 


Efficacy results

	ITT (TPS≥1%) N=135		PD-L1-high (TPS≥50%) N=58		PD-L1-low (TPS1-49%) N=77
Arms	tiragolumab + Tecentriq (n=67)	placebo + Tecentriq (n=68)	tiragolumab + Tecentriq (n=29)	placebo + Tecentriq (n=29)	tiragolumab+ Tecentriq (n=38)	placebo + Tecentriq (n=39)
ORR, % (95% CI)	31.3 (19.5, 43.2)	16.2 (6.7, 25.7)	55.2 (35.3, 75.0)	17.2  (1.8, 32.7)	13.2 (1.15, 25.2)	15.4 (2.8, 28.0)
Odds ratio (95% CI)	2.57 (1.07,6.14)*		5.91 (1.76,19.81)		0.83 (0.23, 3.00)
Median PFS (95% CI)	5.4